Moderna has announced its first autoimmune candidate to enter the clinic as the company looks to expand the applications for its messenger RNA technology across different therapeutic areas.
According to the drugmaker, the first participant has been dosed in the phase 1 study of mRNA-6231, the company’s mRNA-encoded IL-2 modified for the expansion of regulatory T cells. The trial is a first‑in‑human, dose‑escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA‑6231 in healthy adult participants following subcutaneous administration of a single dose of mRNA‑6231. The candidate is also Moderna’s first subcutaneously administered therapeutic program.
The Cambridge, Massachusetts-based drugmaker now has active clinic programs in five different therapeutic areas: infectious disease, oncology, cardiovascular, rare disease, and autoimmune disease.
Read the press release
